Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06011733
PHASE3

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Sponsor: UCB Biopharma SRL

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).

Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

133

Start Date

2023-10-31

Completion Date

2025-02-05

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

OTHER

Placebo

Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.

DRUG

Bimekizumab

Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.

Locations (18)

Ps0041 20023

Beijing, China

Ps0041 20247

Beijing, China

Ps0041 20306

Beijing, China

Ps0041 20117

Guangzhou, China

Ps0041 20311

Guangzhou, China

Ps0041 20313

Guangzhou, China

Ps0041 20022

Hangzhou, China

Ps0041 20193

Hangzhou, China

Ps0041 20296

Hangzhou, China

Ps0041 20312

Jinan, China

Ps0041 20318

Jinan, China

Ps0041 20310

Ningbo, China

Ps0041 20308

Shanghai, China

Ps0041 20184

Shenzhen, China

Ps0041 20136

Tianjin, China

Ps0041 20120

Wuhan, China

Ps0041 20314

Wuxi, China

Ps0041 20309

Xi'an, China